Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab in Patients With Myelofibrosis
NCT04517851Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elotuzumab in myelofibrosis (MF), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
elotuzumab
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04517851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517851.